BMJ Open Gastroenterology最新文献

{"title":"Efficacy of a nasal mask oxygen kit versus regular nasal cannula in sedated gastrointestinal endoscopy: a multicentre, randomised clinical trial.","authors":"Xiangyang Cheng, Xiao Zhang, Jie Zhang, Zhenhua Hu, Jiaqiang Zhang, Qiuyue Lian, Xibing Ding, Yanhua He, Muyan Shi, Yuhan Zhang, Ming Tian, Huarong Zheng, Zhilin Li, Yang Wang, Weifeng Yu, Jianlin Shao, Diansan Su","doi":"10.1136/bmjgast-2025-001834","DOIUrl":"10.1136/bmjgast-2025-001834","url":null,"abstract":"<p><strong>Objective: </strong>The incidence of hypoxia in painless gastrointestinal endoscopy is not negligible. A nasal mask oxygen kit may reduce the incidence of hypoxia compared with a regular nasal cannula.</p><p><strong>Methods: </strong>This multi-centre, randomised, open-label clinical trial took place from 1 September 2022 to 6 June 2023 in three Chinese teaching hospitals. Participants were randomly assigned 1:1 to either the intervention or the control group. Before induction of anaesthesia, a nasal cannula was used in the control group, and a nasal mask oxygen kit was used in the intervention group. The primary outcome was hypoxia (peripheral capillary oxygen saturation (SpO₂) ≥75% but <90% for <60 s). Secondary outcomes were subclinical respiratory depression (SpO₂≥90% but <95%), severe hypoxia (SpO₂<75% or SpO₂≥75% but <90% for ≥60 s) and other adverse events.</p><p><strong>Results: </strong>Among the 1204 initially enrolled patients, 1197 completed the study, with 597 randomised to the nasal mask oxygen kit group and 600 to the control group. Compared with the control group, the nasal mask oxygen kit significantly reduced the incidence of hypoxia during gastrointestinal endoscopy under sedation (12.5% vs 7.4%; rate difference (RD) = 0.051; 95% CI 0.018 to 0.085; p=0.003), subclinical respiratory depression (13% vs 9.4%; RD = 0.036; 95% CI 0.0005 to 0.072; p=0.047) and total adverse events (27.5% vs 18.6%; RD = 0.089; 95% CI 0.042 to 0.137; p<0.001). There was no difference in the incidence of severe hypoxia (1.17% vs 0.7%; RD = 0.005; 95% CI -0.006 to 0.016; p>0.05).</p><p><strong>Conclusions: </strong>The nasal mask oxygen kit can decrease the incidence of hypoxia in patients with American Society of Anesthesiologists class I/II undergoing gastrointestinal endoscopy under propofol and fentanyl sedation.</p><p><strong>Trial registration number: </strong>NCT05405530.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12232457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing ultrasonographic detection of hepatocellular carcinoma with artificial intelligence: current applications, challenges and future directions.","authors":"Janthakan Wongsuwan, Teeravut Tubtawee, Sitang Nirattisaikul, Pojsakorn Danpanichkul, Wisit Cheungpasitporn, Sitthichok Chaichulee, Apichat Kaewdech","doi":"10.1136/bmjgast-2025-001832","DOIUrl":"10.1136/bmjgast-2025-001832","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with early detection playing a crucial role in improving survival rates. Artificial intelligence (AI), particularly in medical image analysis, has emerged as a potential tool for HCC diagnosis and surveillance. Recent advancements in deep learning-driven medical imaging have demonstrated significant potential in enhancing early HCC detection, particularly in ultrasound (US)-based surveillance.</p><p><strong>Method: </strong>This review provides a comprehensive analysis of the current landscape, challenges, and future directions of AI in HCC surveillance, with a specific focus on the application in US imaging. Additionally, it explores AI's transformative potential in clinical practice and its implications for improving patient outcomes.</p><p><strong>Results: </strong>We examine various AI models developed for HCC diagnosis, highlighting their strengths and limitations, with a particular emphasis on deep learning approaches. Among these, convolutional neural networks have shown notable success in detecting and characterising different focal liver lesions on B-mode US often outperforming conventional radiological assessments. Despite these advancements, several challenges hinder AI integration into clinical practice, including data heterogeneity, a lack of standardisation, concerns regarding model interpretability, regulatory constraints, and barriers to real-world clinical adoption. Addressing these issues necessitates the development of large, diverse, and high-quality data sets to enhance the robustness and generalisability of AI models.</p><p><strong>Conclusions: </strong>Emerging trends in AI for HCC surveillance, such as multimodal integration, explainable AI, and real-time diagnostics, offer promising advancements. These innovations have the potential to significantly improve the accuracy, efficiency, and clinical applicability of AI-driven HCC surveillance, ultimately contributing to enhanced patient outcomes.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of a digital lifestyle intervention (VITALISE) to support weight loss in patients with MASLD in routine secondary care.","authors":"Leah Avery, Hollie Smith, Rebecca Livingston, Stuart McPherson, Alison Innerd, Kate Hallsworth","doi":"10.1136/bmjgast-2025-001771","DOIUrl":"10.1136/bmjgast-2025-001771","url":null,"abstract":"<p><strong>Objective: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide. Weight loss, achieved by changes to lifestyle behaviours, is the recommended management approach. However, patients find this challenging. A MASLD-specific digital behavioural intervention (interVention to promote lIfesTyle change in metabolic dysfunction-Associated steatotic LIver diseaSE, VITALISE) to target changes in dietary and physical activity behaviours was developed to support weight loss. This study assessed the feasibility and acceptability of delivering VITALISE in routine secondary care.</p><p><strong>Methods: </strong>A single-centre, one-arm feasibility study recruited participants from November 2022 to May 2023. VITALISE included MASLD-specific education, provision of self-regulation tools (ie, goal setting, food monitoring, step tracking, weight monitoring) and monthly health coaching appointments by telephone. Patients had access to VITALISE for 6 months. Primary outcomes were feasibility (recruitment, uptake, engagement, adherence, and follow-up rates) and acceptability (patient views). Secondary outcomes were body weight, liver enzymes, liver stiffness, blood pressure, lipid profile, glycated hemoglobin (HbA1c), physical activity and patient activation.</p><p><strong>Results: </strong>35 patients (mean age 54 years; 69% male) with MASLD were recruited to VITALISE (recruitment rate 59%). Of the 35 enrolled, 83% activated their VITALISE account. Patient interviews supported acceptability. At 6 months, mean weight loss was 4.0 kg (3.5%) and alanine transaminase reduced by 27%. A decrease in daily sedentary time and an increase in light physical activity were observed. Self-reported leisure-time physical activity and patient activation increased from baseline to 6-month follow-up.</p><p><strong>Conclusions: </strong>VITALISE was feasible and acceptable to deliver in routine secondary care. Weight loss and improvements in lifestyle behaviours and liver enzymes were observed. Findings will inform intervention optimisation and future large-scale evaluation.</p><p><strong>Trial registration number: </strong>ISRCTN12893503.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of distal adenoma and hyperplastic polyp characteristics with long-term proximal colon cancer risk: a secondary, observational analysis of data from the UK Flexible Sigmoidoscopy Screening Trial.","authors":"Rhea Harewood, Kate Wooldrage, Emma C Robbins, James Kinross, Christian von Wagner, Amanda J Cross","doi":"10.1136/bmjgast-2025-001787","DOIUrl":"10.1136/bmjgast-2025-001787","url":null,"abstract":"<p><strong>Objectives: </strong>Colorectal cancer screening with flexible sigmoidoscopy focuses on the distal colorectum, but it is unclear which distal polyp characteristics are associated with future proximal colon cancer incidence. We examined associations between distal adenoma or hyperplastic polyp characteristics and long-term incident proximal colon cancer.</p><p><strong>Methods: </strong>In secondary, observational analyses of UK Flexible Sigmoidoscopy Screening Trial data, we obtained data on the number and size of distal hyperplastic polyps (n=4872) and adenomas (n=4581), adenoma histology and dysplasia from endoscopy and pathology reports for screened asymptomatic participants. Adjusted HRs and 95% CIs for the association between distal polyp characteristics and proximal colon cancer incidence were estimated using multivariable Cox proportional hazard models.</p><p><strong>Results: </strong>Over a median of 20.7 years of follow-up (IQR 16.5-21.7), 110 proximal colon cancers were diagnosed among participants with distal adenomas and 96 were diagnosed among those with only distal hyperplastic polyps detected at baseline. Larger adenoma size (6-9 mm vs ≤5 mm: HR 1.67 (95%CI: 1.07 to 2.59) and ≥10 mm vs ≤5 mm: HR 2.08 (95%CI: 0.98 to 4.43); p=0.037) and high-grade (vs low-grade) adenoma dysplasia (HR 2.82, 95% CI: 1.34 to 5.93; p=0.012) at baseline were positively associated with proximal colon cancer incidence. No associations were observed for distal adenoma number overall or histology, or the number or size of hyperplastic polyps and proximal colon cancer incidence.</p><p><strong>Conclusions: </strong>We found some evidence that larger distal adenomas and those with high-grade dysplasia at baseline were positively associated with proximal colon cancer incidence. Larger studies are needed to confirm these findings.</p><p><strong>Trial registration number: </strong>ISRCTN28352761.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12186034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in surgical treatment of inflammatory bowel disease following introduction of biological drugs in Norway and Sweden.","authors":"Amanda Högdén, Vera Perrin, Hans-Olov Adami, Mette Kalager, Tine Jess, Weimin Ye, Jessica Young, Lise Mørkved Helsingen, Erle Refsum, Johannes Blom","doi":"10.1136/bmjgast-2025-001828","DOIUrl":"10.1136/bmjgast-2025-001828","url":null,"abstract":"<p><strong>Objective: </strong>The advent of biological drugs has revolutionised management of inflammatory bowel disease (IBD). However, the extent to which these novel pharmacological drugs have reduced the need for surgical treatment remains incompletely quantified.We aimed to investigate the risk of first, major surgery in IBD in a population-based, large epidemiological study.</p><p><strong>Methods: </strong>We empanelled a cohort comprising all 85 974 patients diagnosed with ulcerative colitis (UC) and 42 760 with Crohn's disease (CD) in Norway and Sweden in 1987 through 2017. We used log-rank tests to compare the cumulative probability of surgical treatment for UC and CD. Using multivariable Cox proportional hazards models, we estimated hazard ratios (HR) with 95% CIs by year of diagnosis, age, sex and extent of disease.</p><p><strong>Results: </strong>During a mean follow-up of 9.9 years, surgery was undertaken in 11 187 (13.0%) patients with UC (12.3 per 1000 person-years) and in 11 307 (26.4%) patients with CD (30.0 per 1000 person-years). In UC, the cumulative 5-year probability of surgery decreased from 16.2% in patients diagnosed in 1987-1994 to 5.8% in those diagnosed in 2011-2017 (p<0.001). In CD, the corresponding decline was from 30.1% to 13.9% (p<0.001). In multivariable analyses, the likelihood of surgical treatment decreased during the study period by 61% (HR 0.39, 95% CI 0.36 to 0.42) in UC and by 31% (HR 0.69, 95% CI 0.65 to 0.75) in CD.</p><p><strong>Conclusions: </strong>Following the introduction of biologic drugs, the need for surgical treatments has been dramatically reduced in patients with UC and moderately reduced in patients with CD.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic mapping of registered interventional studies addressing the top 10 research priorities in Barrett's oesophagus and gastro-oesophageal reflux disease.","authors":"Champika Gamakaranage, Elizabeth Ratcliffe, James Britton, Thomas Butler, Richard Keld, Neeraj Prasad, Shaheen Hamdy, John McLaughlin, Yeng Ang","doi":"10.1136/bmjgast-2025-001738","DOIUrl":"10.1136/bmjgast-2025-001738","url":null,"abstract":"<p><strong>Objectives: </strong>The top 10 research priorities (RPs) for Barrett's oesophagus (BO) were published in 2017. This study aimed to identify the current research landscape on addressing RPs.</p><p><strong>Design: </strong>Systematic mapping review.</p><p><strong>Data sources: </strong>ClinicalTrials.gov, EU Clinical Trials Register and ISRCTN registry.</p><p><strong>Eligibility criteria: </strong>Adult (>18 years) interventional studies registered in those three registers from 31 August 2017 to 1 July 2024 and addressing any of the top 10 RPs were eligible.</p><p><strong>Data extraction and synthesis: </strong>Two researchers extracted data using prespecified tables, from the three registers and pooled them together.</p><p><strong>Results: </strong>We identified clinical trials (n=735) registered in the last 7 years (ClinicalTrials.gov (611), EU Clinical Trials (63), ISRCTN (61)), and 244 were included as they addressed RPs, after removing 14 duplicates. Most studies (168/244, 69%) addressed RP8 (searching alternative treatments for reflux), including medicinal products (86/168 (51%)), surgical methods (29/168 (17%)) and endoscopic methods (26/168 (15%)). There were 41/244 (17%) trials registered aiming investigations for screening and surveillance of BO in a primary care setting (RP3). 92% of studies were distributed among RP8, RP3 and RP5. The remaining RPs (RP1, RP2, EP4, RP6, RP7 and RP9) had only 8% of 244 studies, while the RP10 had none.</p><p><strong>Conclusion: </strong>A higher concentration of studies on RP8, RP3 and RP5 may demonstrate the high clinical and global commercial demand on them, while the scarcity of trials for RP1, RP2, RP4, RP6, RP7, RP9 and RP10 unveils gaps in research meeting priorities. This unequal distribution of the trial landscape raises the question: do we correctly address the RPs?</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity.","authors":"","doi":"10.1136/bmjgast-2022-000871corr1","DOIUrl":"10.1136/bmjgast-2022-000871corr1","url":null,"abstract":"","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing water-assisted colonoscopy in beginner endoscopists: a randomised controlled trial.","authors":"Nuttida Manoros, Nithi Thinrungroj, Wasuwit Wanchaitanawong, Kanokwan Pinyopornpanish, Phuripong Kijdamrongthum, Apinya Leerapun, Taned Chitapanarux, Satawat Thongsawat, Ong-Ard Praisontarangkul","doi":"10.1136/bmjgast-2024-001561","DOIUrl":"10.1136/bmjgast-2024-001561","url":null,"abstract":"<p><strong>Objective: </strong>To compare water-assisted colonoscopy (WAC) using the water immersion technique with conventional carbon dioxide insufflation colonoscopy (CC) in novice endoscopists, focusing on procedure time, safety and learning curves.</p><p><strong>Methods: </strong>We conducted a prospective, randomised (1:1), single-centre trial at Chiang Mai University Hospital, Thailand. Six gastroenterology fellows with <150 prior colonoscopies received standardised training before performing elective screening colonoscopies using either WAC or CC techniques. Patients were randomly assigned to WAC or CC groups. The primary outcome was caecal intubation time (CIT). Secondary outcomes included technical failure, procedural difficulty, patient discomfort, complications, withdrawal time and adenoma detection rate (ADR).</p><p><strong>Results: </strong>Of 250 randomised patients, 230 completed the protocol (WAC, n=113; CC, n=117). Mean CIT was comparable between groups (10.6±4.2 min vs 9.8±3.9 min; p=0.35). Technical failure occurred in 6.2% of WAC and 5.1% of CC procedures, with no significant differences in procedural difficulty ratings, analgesic requirements or patient discomfort scores. ADR was similar between arms (40.7% vs 33.3%; p=0.25). Learning curves demonstrated parallel, progressive reductions in CIT among fellows in both groups.</p><p><strong>Conclusion: </strong>WAC is a safe and effective alternative to CC for novice endoscopists, with similar procedure times, learning curves and safety profiles. These findings support the inclusion of WAC in gastroenterology training programmes.</p><p><strong>Trial registration number: </strong>TCTR20230324001.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12104895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of user experiences, perceptions and attitudes towards faecal immunochemical testing (FIT) for risk-stratified colonoscopy in people with Lynch syndrome.","authors":"Anne Lincoln, Jo Waller, Sally Benton, Peter Sasieni, Kevin J Monahan","doi":"10.1136/bmjgast-2025-001751","DOIUrl":"https://doi.org/10.1136/bmjgast-2025-001751","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluates the experiences, perceptions, and attitudes of people with Lynch syndrome (LS) towards faecal immunochemical testing (FIT) as an adjunct to colonoscopy for colorectal cancer surveillance.</p><p><strong>Methods: </strong>A mixed-methods design included two cohorts: an emergency clinical service during the COVID-19 pandemic and a longitudinal research initiative. Paper-based surveys assessed user experiences and attitudes using Likert scales and open-ended questions. Quantitative data were analysed for response patterns, while thematic analysis explored qualitative feedback.</p><p><strong>Results: </strong>Among 85% of participants who rated FIT positively, 90% were confident in using the test correctly. Women reported higher anxiety (7.8%) compared with men (2.0%, p=0.045). Thematic analysis revealed gratitude for FIT's convenience during healthcare disruptions but emphasised concerns about its accuracy.</p><p><strong>Conclusions: </strong>FIT is widely perceived as an acceptable supplemental tool among surveyed people with LS, who appreciate its potential to reduce intervals between colonoscopies without compromising surveillance quality. Ongoing patient engagement is crucial to addressing concerns about FIT's reliability. Future research should evaluate long-term outcomes and explore diverse population perspectives to guide FIT implementation in LS surveillance.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ending nuclear weapons, before they end us.","authors":"Chris Zielinski","doi":"10.1136/bmjgast-2025-001891","DOIUrl":"10.1136/bmjgast-2025-001891","url":null,"abstract":"","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}